CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
carbidopa-levodopa 25-100 mgdrug
Likely dose
carbidopa-levodopa 25-100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03197493
NCT03197493Phase 2Completed
CompareCT.gov

Extension of Protocol 002, Carbidopa-levodopa in Neovascular Extension of Protocol 002, Carbidopa-levodopa in Neovascular AMD

Snyder, Robert W., M.D., Ph.D., P.C.·interventional·Posted Jun 23, 2017·Updated Sep 12, 2025

In Brief

A Phase 2 clinical trial evaluating carbidopa-levodopa 25-100 mg for Macula; Degeneration and Retina. Completed, enrolled 35 participants across 1 site.

Detailed Summary

This protocol is an extension of protocol 0002, Proof of Concept and Dose Ranging Study of carbidopa-levodopa in Neovascular AMD. that is a 3 month study of escalating doses of carbidopa-levodopa in neovascular AMD. This trial is a 9 month extension for patients who successfully complete protocol 0002 and wish to continue carbidopa-levodopa therapy. It will use the two higher dose regimens of protocol 0002. these will be assigned according to how well the higher dose was tolerated in protocol 0002.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacula; Degeneration, Retina
CountriesUnited States
CollaboratorsSnyder Biomedical Corporation

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 23, 2017
Enrollment StartAug 1, 2017
Primary CompletionJul 9, 2020
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.0 years ago

Interventions

carbidopa-levodopa 25-100 mgdrug

High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID